您當前的位置:首頁 > 關于云克 > 發展歷程

發展歷程

/FootPrint

十年征程

THE TRACE OF 10 YEARS
    1997年,歷經八年科研,中國核動力研究設計院同位素應用研究所成功研制我國自六十年代起至今兩個國產核素藥物之一——锝[99Tc]亞甲基二膦酸鹽注射液。該產品獲得“國家發明專利證書”以及“國家重點新產品證書”。從此,我們從以前單純的放免試劑和體內顯像試劑供應商逐漸豐富發展為以核素藥品供應為主的核技術專業服務供應商。
   In 1997, the Chengdu Isotope Application Institution(CIAI) of the Nuclear Power Institute of China successfully invented the technetium[99Tc] methylenediphosphonate injection (YUNKE) which was the 2nd radiopharmaceuticals developed in our country since 1960s. From then on, the CIAI and latter the CYPC gradually developed to be a special enterprise providing advanced products and services in the field of diagnostic nuclear medicine and therapeutic nuclear medicine.
    2000年,正式獲得锝[99Tc]亞甲基二膦酸鹽注射液生產批文。同年,獲得另外兩個產品專利。
   In 2000, YUNKE was approved for formal manufacture by the SFDA. Besides, two new drugs were patented.
    2001年10月,云克藥業有限責任公司成立,同年獲得“成都市高新技術企業認定證書”。
   In Oct., 2001, CYPC was established and was certificated as ‘Chengdu High-tech Enterprise’.
    2002年,云克藥業成為行業內首家獲得GMP認證證書的核素藥物生產企業。
   In 2002, CYPC was approved for the Good Manufacturing Practices (GMP) by the SFDA. And it was the 1st enterprise in the radiopharmaceuticals field. 
    2002年,舉辦“云克專題國際研討會”,會上中外專家就云克藥物的研究及應用進行了熱烈的專題討論,為未來幾年內云克藥物的科研和臨床應用提出了大量寶貴意見和建議。
   In 2002, a special seminar on YUNKE was hold in Chengdu. On the seminar, experts discussed the mechanisms of YUNKE on treatment of RA, AS etc. and exchanged experiences on application of YUNKE.
    2002年,國際原子能機構和國際衛生組織的專家對我公司項目進行了考察。
   In 2002, experts from the International Atomic Energy Agency(IAEA) and the World Health Organization(WHO) visited the CYPC.
    2003年,國務院學位委員會授權我公司設立“核技術及應用博士點”。
   In 2003, the CYPC was designated to confer the doctoral degrees of nuclear technology and application program by the Evaluation Committee of Academic Degrees of the State Council.
    2006年, I-125密封籽源項目研發成功,預計將于2009年正式推向市場,并進行相關配套產品研發。
   In 2006, 125I sealed seeds source was developed successfully and was expected to enter market in 2009. Now, radioactive stent using 125I sealed seeds source is under development.
    2006年,與成都市紅十字會以及成都市青羊區中醫醫院合作,開展“救治類風濕關節炎特困患者愛心活動”。
   In 2006, cooperated with the Red Cross Society of China, Chengdu City Branch and the Qingyang Section Herbalist Hospital, the CYPC sponsored a patient assistance social activity by fee-free drug(YUNKE) providing and treatment for the especially poor patients of RA.
    2006年,我公司被授予“四川省建設創新型企業”稱號。
   In Oct., 2001, CYPC was established and was certificated as ‘Constructive innovational Enterprise of Sichuan Province’.
 
 
企業郵局 | 聯系我們 | 版權聲明 | 法律聲明 | 設為首頁 | 加入收藏 | Copyright?成都云克藥業有限責任公司 版權所有 | 蜀ICP備11019119號 互聯網藥品信息服務資格證書編號:(川)-非經營性-2016-0061 本網站未發布麻醉藥品、精神藥品、醫療用毒性藥品、戒毒藥品和醫療機構制劑的產品信息 聲明:本站部分圖片信息來自網絡,如涉及到版權,請及時聯系我們

川公網安備 51019002000571號